NCT03164616 2026-03-13
POSEIDON
AstraZeneca
Phase 3 Active not recruiting
AstraZeneca
Guangzhou University of Traditional Chinese Medicine
Mario Negri Institute for Pharmacological Research
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Ono Pharmaceutical Co. Ltd
Peking University Cancer Hospital & Institute